Beta Bionics, Inc. (BBNX): who owns it and who trades it
As of Nov 16, 2026, BBNX insiders reported 54 open-market sales worth $5.4M and no purchases in the last 12 months, with 72% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark Hopman (Chief Commercial Officer), with $2.3M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Beta Bionics
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns BBNX
131 funds and institutions reported BBNX shares worth $757M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Eventide Asset Management, LLC with 14.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Eventide Asset Management, LLC | 6.25M | 14.03% | $98.1M | +5% |
| Soleus Capital Management, L.P. | 4.39M | 9.86% | $68.8M | +1% |
| Morgan Stanley | 4.27M | 9.58% | $66.9M | +1% |
| Sands Capital Alternatives, LLC | 3.71M | 8.32% | $58.1M | No change |
| BlackRock, Inc. | 3.34M | 7.50% | $52.3M | +10% |
| Point72 Asset Management, L.P. | 2.25M | 5.06% | $35.3M | -11% |
| Vanguard Capital Management LLC | 1.78M | 4.00% | $27.9M | +3% |
| Vestal Point Capital, LP | 1.60M | 3.59% | $25.1M | -28% |
| Rtw Investments, LP | 1.50M | 3.37% | $23.5M | -25% |
| Deerfield Management Company, L.P. | 1.32M | 2.97% | $20.7M | No change |
| Omega Fund Management, LLC | 1.32M | 2.95% | $20.6M | No change |
| Eversept Partners, LP | 1.25M | 2.80% | $19.6M | -12% |
| Divisadero Street Capital Management, LP | 1.11M | 2.50% | $17.5M | – |
| Geode Capital Management, LLC | 1.07M | 2.41% | $16.8M | +15% |
| State Street Corp | 970,192 | 2.18% | $15.2M | +3% |
| Millennium Management LLC | 956,244 | 2.15% | $15M | +11% |
| Balyasny Asset Management L.P. | 855,682 | 1.92% | $13.4M | +38% |
| Perceptive Advisors LLC | 832,944 | 1.87% | $13.1M | -1% |
| JPMorgan Chase & Co | 703,356 | 1.58% | $12M | – |
| Bruce & Co., Inc. | 665,700 | 1.49% | $10.4M | +21% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, BBNX insiders reported $0 of open-market purchases and $5.4M of sales. 72% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Stephen Feider | CFO | Sale plan | 8,874 | $17.21 | $153K | Form 4 |
| Nov 9, 2026 | Stephen Feider | CFO | Sale plan | 744 | $17.00 | $12.6K | Form 4 |
| Nov 5, 2026 | Stephen Feider | CFO | Sale plan | 382 | $17.04 | $6.5K | Form 4 |
| Nov 2, 2026 | Mark Hopman | Chief Commercial Officer | Sale plan | 370 | $16.90 | $6.3K | Form 4 |
| Oct 27, 2026 | Mike Mensinger | Chief Product Officer | Sale plan | 2,650 | $22.00 | $58.3K | Form 4 |
| Oct 26, 2026 | Mark Hopman | Chief Commercial Officer | Sale plan | 821 | $20.00 | $16.4K | Form 4 |
| Oct 14, 2026 | Mark Hopman | Chief Commercial Officer | Sale | 775 | $17.35 | $13.4K | Form 4 |
| Oct 1, 2026 | Mark Hopman | Chief Commercial Officer | Sale | 370 | $18.96 | $7K | Form 4 |
| Sep 22, 2026 | Christy Jones | Director | Sale plan | 6,430 | $23.00 | $148K | Form 4 |
| Sep 16, 2026 | Mark Hopman | Chief Commercial Officer | Sale plan | 30,779 | $20.13 | $620K | Form 4 |
| Sep 16, 2026 | Mike Mensinger | Chief Product Officer | Sale plan | 2,650 | $22.00 | $58.3K | Form 4 |
| Sep 14, 2026 | Mark Hopman | Chief Commercial Officer | Sale plan | 775 | $15.52 | $12K | Form 4 |
| Sep 9, 2026 | Mark Hopman | Chief Commercial Officer | Sale plan | 35,994 | $18.46 | $664K | Form 4 |
| Sep 9, 2026 | Mark Hopman | Chief Commercial Officer | Sale plan | 36,870 | $18.46 | $681K | Form 4 |
| Sep 3, 2026 | Sean Saint | CEO | Sale plan | 5,641 | $20.08 | $113K | Form 4 |
| Sep 2, 2026 | Mark Hopman | Chief Commercial Officer | Sale | 5,327 | $19.11 | $102K | Form 4 |
| Sep 2, 2026 | Steven Jon Russell | Chief Medical Officer | Sale | 4,221 | $19.11 | $80.7K | Form 4 |
| Sep 2, 2026 | Mike Mensinger | Chief Product Officer | Sale | 4,375 | $19.11 | $83.6K | Form 4 |
| Sep 2, 2026 | Stephen Feider | CFO | Sale | 6,675 | $19.11 | $128K | Form 4 |
| Sep 2, 2026 | Sean Saint | CEO | Sale | 16,867 | $19.11 | $322K | Form 4 |
| Jun 29, 2026 | Stephen Feider | CFO | Sale plan | 4,896 | $17.03 | $83.4K | Form 4 |
| Jun 26, 2026 | Stephen Feider | CFO | Sale plan | 5,104 | $17.05 | $87K | Form 4 |
| Jun 24, 2026 | Mark Hopman | Chief Commercial Officer | Sale plan | 1,258 | $15.01 | $18.9K | Form 4 |
| Jun 24, 2026 | Christy Jones | Director | Sale plan | 1,406 | $15.00 | $21.1K | Form 4 |
| Jun 4, 2026 | Mark Hopman | Chief Commercial Officer | Sale plan | 275 | $12.31 | $3.4K | Form 4 |
| Jun 4, 2026 | Christy Jones | Director | Sale plan | 2,811 | $14.00 | $39.4K | Form 4 |
| Jun 2, 2026 | Mike Mensinger | Chief Product Officer | Sale | 4,378 | $12.61 | $55.2K | Form 4 |
| Jun 2, 2026 | Mark Hopman | Chief Commercial Officer | Sale | 5,329 | $12.61 | $67.2K | Form 4 |
| Jun 2, 2026 | Steven Jon Russell | Chief Medical Officer | Sale | 4,222 | $12.61 | $53.2K | Form 4 |
| Jun 2, 2026 | Stephen Feider | CFO | Sale | 6,676 | $12.61 | $84.2K | Form 4 |
| Jun 2, 2026 | Sean Saint | CEO | Sale | 16,872 | $12.61 | $213K | Form 4 |
| May 22, 2026 | Adam Lezack | Director | Sale plan | 998 | $11.21 | $11.2K | Form 4 |
| May 21, 2026 | Christy Jones | Director | Sale plan | 1,998 | $9.95 | $19.9K | Form 4 |
| May 21, 2026 | Adam Lezack | Director | Sale plan | 1,000 | $9.95 | $9.9K | Form 4 |
| Mar 4, 2026 | Mark Hopman | Chief Commercial Officer | Sale plan | 353 | $11.57 | $4.1K | Form 4 |
| Mar 2, 2026 | Mark Hopman | Chief Commercial Officer | Sale | 834 | $12.36 | $10.3K | Form 4 |
| Mar 2, 2026 | Steven Jon Russell | Chief Medical Officer | Sale | 1,026 | $12.36 | $12.7K | Form 4 |
| Mar 2, 2026 | Mike Mensinger | Chief Product Officer | Sale | 1,064 | $12.36 | $13.2K | Form 4 |
| Mar 2, 2026 | Stephen Feider | CFO | Sale | 1,428 | $12.36 | $17.7K | Form 4 |
| Mar 2, 2026 | Sean Saint | CEO | Sale | 3,384 | $12.36 | $41.8K | Form 4 |
| Jan 6, 2026 | Mike Mensinger | Chief Product Officer | Sale plan | 2,200 | $30.10 | $66.2K | Form 4 |
| Jan 2, 2026 | Mike Mensinger | Chief Product Officer | Sale plan | 7,200 | $29.56 | $213K | Form 4 |
| Jan 2, 2026 | Mike Mensinger | Chief Product Officer | Sale plan | 600 | $30.20 | $18.1K | Form 4 |
| Jan 2, 2026 | Stephen Feider | CFO | Sale plan | 20,000 | $29.53 | $591K | Form 4 |
| Dec 4, 2025 | Mark Hopman | Chief Commercial Officer | Sale plan | 2,061 | $30.66 | $63.2K | Form 4 |
| Dec 2, 2025 | Mark Hopman | Chief Commercial Officer | Sale plan | 856 | $29.34 | $25.1K | Form 4 |
| Dec 2, 2025 | Steven Jon Russell | Chief Medical Officer | Sale | 1,025 | $29.34 | $30.1K | Form 4 |
| Dec 2, 2025 | Mike Mensinger | Chief Product Officer | Sale | 1,063 | $29.34 | $31.2K | Form 4 |
| Dec 2, 2025 | Stephen Feider | CFO | Sale | 1,427 | $29.34 | $41.9K | Form 4 |
| Dec 2, 2025 | Sean Saint | CEO | Sale | 3,278 | $29.34 | $96.2K | Form 4 |
| Dec 1, 2025 | Adam Lezack | Director | Sale plan | 906 | $29.35 | $26.6K | Form 4 |
| Dec 1, 2025 | Adam Lezack | Director | Sale plan | 500 | $29.91 | $15K | Form 4 |
| Dec 1, 2025 | Maria Palasis | Director | Sale plan | 906 | $29.33 | $26.6K | Form 4 |
| Dec 1, 2025 | Maria Palasis | Director | Sale plan | 500 | $29.96 | $15K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Mark Hopman | Chief Commercial Officer | – | $2.3M | Nov 2, 2026 |
| Stephen Feider | Chief Financial Officer | – | $1.2M | Nov 11, 2026 |
| Sean Saint | President & CEO, Director | – | $786K | Sep 3, 2026 |
| Mike Mensinger | Chief Product Officer | – | $597K | Oct 27, 2026 |
| Christy Jones | Director | – | $228K | Sep 22, 2026 |
| Steven Jon Russell | Chief Medical Officer | – | $177K | Sep 2, 2026 |
| Adam Lezack | Director | – | $62.7K | May 22, 2026 |
| Maria Palasis | Director | – | $41.6K | Dec 1, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BBNX short interest
Moderate short interest. 9.2% of BBNX shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 12%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 4.98M BBNX shares were sold short, 9.2% of the shares outstanding, down 28.0% from the report before. At the average daily volume of 1.27M shares, buying them all back would take about 3.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.98M | 9.16% | -28% | 1.27M | 3.9 |
| Oct 15, 2026 | 6.92M | 15.37% | +14% | 936,755 | 7.4 |
| Sep 30, 2026 | 6.05M | 13.44% | -43% | 1.86M | 3.2 |
| Sep 15, 2026 | 10.62M | 23.60% | +13% | 1.07M | 9.9 |
| Aug 31, 2026 | 9.40M | 20.90% | +25% | 1.04M | 9.0 |
| Aug 14, 2026 | 7.49M | 16.66% | -1% | 1.37M | 5.5 |
| Jul 31, 2026 | 7.60M | 16.90% | +15% | 1.26M | 6.0 |
| Jul 15, 2026 | 6.61M | 14.83% | -3% | 948,708 | 7.0 |
| Jun 30, 2026 | 6.82M | 15.30% | +46% | 1.16M | 5.9 |
| Jun 15, 2026 | 4.67M | 10.49% | -10% | 1.04M | 4.5 |
| May 29, 2026 | 5.20M | 11.67% | -9% | 721,094 | 7.2 |
| May 15, 2026 | 5.69M | 12.76% | -8% | 624,527 | 9.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Beta Bionics company events
Beta Bionics filed 10 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 27, 2026.
- Oct 27, 2026ResultsReleased financial results. Filing
- Sep 17, 2026AnnouncementBeta Bionics, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Piper Sandler & Co., Wells Fargo Securities, LLC and Leerink Partners LLC, as representatives of the several underwriters named therein, relating to the issuance and sale in a public offering of 7,652,175… Filing
- Sep 15, 2026AnnouncementWe announced FDA clearance of Mint, our patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and Android users. Filing
- Jul 29, 2026ResultsReleased financial results. Filing
- May 22, 2026VoteReported shareholder vote results. Filing
- May 21, 2026AnnouncementThe Company announced that it expects to fully commercialize Mint by the end of the second quarter of 2027, subject to regulatory clearance by the U.S. Food and Drug Administration. Filing
- Apr 21, 2026ResultsReleased financial results. Filing
- Feb 17, 2026ResultsReleased financial results. Filing
- Jan 30, 2026AnnouncementBeta Bionics, Inc. received a warning letter from the U.S. Food and Drug Administration following inspection of the Company’s facility in Irvine, California that occurred from June 9, 2025 through June 26, 2025. Filing
- Jan 8, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Beta Bionics financials
Famous investors that hold BBNX
5 of the 50 well-known investors we track reported holding BBNX in their latest 13F filing. The largest position is Steve Cohen's, worth $18.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 967,144 | $18.4M | 0.0% | -57% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 187,803 | $3.6M | 0.0% | +194% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 103,450 | $2M | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 61,600 | $1.2M | 0.0% | +445% |
| Israel Englander · Millennium Management | Q3 2026 | 15,915 | $302K | 0.0% | -98% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named BBNX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Point72 Asset Management, L.P. | 13G/A | 1.8% |
| Nov 16, 2026 | Divisadero Street Capital Management, LP | 13G/A | 0.1% |
| Nov 16, 2026 | Divisadero Street Capital Management, LP | 13G/A | 0.1% |
| Nov 16, 2026 | Point72 Asset Management, L.P. | 13G/A | 1.8% |
| Nov 9, 2026 | Soleus Private Equity Fund II, L.P. | 13G/A | 1.8% |
| Nov 9, 2026 | Soleus Private Equity Fund II, L.P. | 13G/A | 1.8% |
| Oct 7, 2026 | T. Rowe Price Associates, Inc. | 13G | 16.6% |
| Oct 7, 2026 | T. Rowe Price Associates, Inc. | 13G | 16.6% |
Questions about Beta Bionics, Inc. (BBNX) stock
Who owns the most BBNX stock?
The largest reported owner of Beta Bionics, Inc. (BBNX) is Eventide Asset Management, LLC, with 14.0% of the company. In total, 131 funds and institutions reported holding BBNX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are BBNX insiders buying or selling?
In the last 12 months, BBNX insiders reported no open-market purchases and 54 sales worth $5.4M. The latest trade was on Nov 11, 2026. See every trade.
What is the short interest in BBNX?
As of Oct 30, 2026, 4.98M BBNX shares were sold short, 9.2% of the shares outstanding, down 28.0% from the report before. At the average daily volume of 1.27M shares, buying them all back would take about 3.9 trading days (days to cover). See the history.
Which famous investors hold BBNX?
5 of the 50 well-known investors we track reported BBNX in their latest 13F filing, including Steve Cohen, Paul Tudor Jones, Ken Griffin. The largest position is worth $18.4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.